Banque Cantonale Vaudoise Sells 18,000 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Banque Cantonale Vaudoise reduced its stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) by 64.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,900 shares of the company’s stock after selling 18,000 shares during the quarter. Banque Cantonale Vaudoise’s holdings in SOPHiA GENETICS were worth $43,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of SOPH. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in SOPHiA GENETICS in the second quarter worth $31,000. Renaissance Technologies LLC bought a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at about $63,000. JPMorgan Chase & Co. lifted its stake in shares of SOPHiA GENETICS by 3,090.2% during the 4th quarter. JPMorgan Chase & Co. now owns 31,392 shares of the company’s stock worth $65,000 after buying an additional 30,408 shares during the last quarter. Jane Street Group LLC acquired a new stake in SOPHiA GENETICS in the 1st quarter worth about $80,000. Finally, Two Sigma Securities LLC acquired a new stake in SOPHiA GENETICS in the 1st quarter worth about $90,000. 36.68% of the stock is owned by institutional investors.

SOPHiA GENETICS Stock Up 0.5 %

Shares of SOPHiA GENETICS stock opened at $3.68 on Monday. The firm’s 50 day moving average is $3.08 and its 200 day moving average is $3.58. SOPHiA GENETICS SA has a 1 year low of $1.77 and a 1 year high of $5.77.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharma customers worldwide.